ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While it is clear that the more potent activity of dasatinib against native and mutant variants of BCR-ABL is, in part, responsible for its clinical efficacy in imatinib-resistant CML, BCR-ABL–independent effects appear to play a role as well.